Quadrature Capital LTD C4 Therapeutics, Inc. Transaction History
Quadrature Capital LTD
- $4.51 Trillion
- Q1 2025
A detailed history of Quadrature Capital LTD transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Quadrature Capital LTD holds 16,009 shares of CCCC stock, worth $22,092. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,009Holding current value
$22,092% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
118Shares Held
63.1MCall Options Held
18.8KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.1MShares$9.8 Million4.2% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$9.63 Million0.92% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$9.43 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.72MShares$9.28 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$6.28 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $67.5M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...